Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00490451 | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma | PHASE2 | COMPLETED | 101 | — | — | Aug 1, 2007 | Feb 1, 2010 | Sep 18, 2019 | 13 | United States, Argentina +1 |
Defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.0). PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
| Arm | Type | Description |
|---|---|---|
| LY573636 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY573636-sodium | DRUG | LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met. |
Inclusion Criteria: * Diagnosis of soft tissue sarcoma that is unresectable or metastatic * Have received one or two (but no more than two) prior treatment regimens for metastatic soft tissue sarcoma, one of which must have included doxorubicin (adriamycin). * Must have stopped all previous treatme...